Context: Insulin resistance in skeletal muscle is a major risk factor for the development of type 2 diabetes in women with polycystic ovary syndrome (PCOS). Despite this, the mechanisms underlying insulin resistance in PCOS are largely unknown.
increased risk of developing metabolic morbidities such as type 2 diabetes (T2D) (2) . Despite the high prevalence of PCOS, the etiology is not well known, although both the environment and PCOS-susceptible genes have been implicated in the development of the syndrome (1) . Only a few studies have examined the effect of epigenetics on PCOS. Recently, we and others demonstrated that women with PCOS have multiple transcriptional and epigenetic changes in adipose tissue that are relevant for development of the disease (3) (4) (5) . Although adipose tissue is involved in the regulation of whole-body glucose homeostasis, skeletal muscle accounts for the vast majority of peripheral glucose uptake. After a meal, almost two-thirds of ingested glucose is taken up by skeletal muscle through insulin-dependent mechanisms, thus giving it a pivotal role in the regulation of peripheral glucose uptake.
Insulin resistance in the skeletal muscle is a major risk factor for the development of T2D in women with PCOS (2) . The mechanisms underlying skeletal muscle insulin resistance in PCOS in vivo are largely unknown but may include impaired mitochondrial oxidative metabolism, reduced insulin-mediated association of phosphatidylinositol 3-kinase with insulin receptor substrate-1, and increased serine phosphorylation of the insulin receptor and insulin receptor substrate-1 (6) (7) (8) (9) (10) (11) .
In a study of twins, the heritability of PCOS was estimated as ;70% (12) , but the genetic variants identified so far by genome-wide association studies explain only a modest proportion of the estimated heritability (13) . Therefore, other factors increasing the susceptibility of this complex metabolic disorder must also be investigated and may include epigenetic mechanisms such as DNA methylation and histone modifications. We hypothesized that epigenetic alterations are present in skeletal muscle from women with PCOS. Therefore, the aims of this study were to investigate genome-wide DNA methylation and gene expression patterns in skeletal muscle from women with PCOS and controls and relate them to phenotypic variation. As a functional validation experiment mimicking PCOS, we isolated and cultured skeletal muscle cells derived from female donors in the presence of insulin and testosterone with or without androgen receptor (AR) blocker and determined the glucose-to-glycogen conversion and the effects on expression of selected genes.
Materials and Methods

Study participants
In total, 21 cases and 21 controls matched for age, weight, and body mass index (BMI) were included in this study, and they were previously described in detail (4) . We successfully collected skeletal muscle biopsies from 17 women with PCOS and from 14 controls. Therefore, all baseline data are given for those included in the analyses of gene expression and DNA methylation ( Table 1 ). All women provided oral and written informed consent. The study was conducted at the Sahlgrenska Academy, University of Gothenburg and at Sahlgrenska University Hospital, Gothenburg, Sweden, in accordance with the Declaration of Helsinki and was approved by the Regional Ethical Review Board of the University of Gothenburg. The study was registered at ClinicalTrials.gov (NCT01457209). After all relevant clinical information was obtained, samples were coded and anonymized. Subject recruitment, exclusion and inclusion criteria, and clinical examination and biochemical analyses are described in detail in the Supplemental Material and Methods.
In addition, cultured skeletal muscle cells, established from biopsies from musculus vastus lateralis from four young, lean, healthy women were used for muscle cell experiments.
Human skeletal muscle cell experiment
Material
Cells were cultured in medium containing DMEM, DMEM-F-12, fetal bovine serum (FBS), penicillin/streptomycin, and Fungizone obtained from Gibco (Invitrogen, Thermo Fischer Scientific, Stockholm, Sweden). The following substances were used to stimulate cells: Testosterone and bicalutamide (CDX; AR antagonist) were purchased from Sigma-Aldrich (Stockholm, Sweden). Charcoal/dextran-treated FBS was obtained from HyClone (Logan, UT). Insulin was purchased from Novo Nordisk (Bagsvaerd, Denmark) and TRI Reagent from Sigma-Aldrich.
Myotube stimulation
In the first condition (i.e., basal), myotubes were cultured in DMEM supplemented with 2% charcoal/dextran-treated FBS and treated with 0.1% ethanol as control, with 100 nM of testosterone or with 100 nM of bicalutamide for 3 days. In the second condition (i.e., insulin 2 hours), myotubes were treated with 0.1% ethanol, with 100 nM of testosterone or with 100 nM of testosterone + 100 nM of bicalutamide for 3 days, plus 2 hours of 60-nM insulin stimulation before harvesting of the cells. Before 2 hours of insulin stimulation, cells were starved for 17 hours. When the AR antagonist bicalutamide was used, myotubes were treated with 0.1% dimethyl sulfoxide or bicalutamide for at least 30 minutes before testosterone was added (14) . In the third condition (i.e., insulin 3 days + insulin 2 hours), myotubes were treated with 0.1% ethanol + insulin 60 nM, with 100 nM of testosterone + insulin 60 nM, or with 100 nM of testosterone + 100 nM of bicalutamide + insulin 60 nM for 3 days, plus 2 hours of 60-nM insulin stimulation before harvesting of the cells. Medium was replaced once a day, and after an overnight serum starvation, differentiated myotubes were harvested followed by extraction of RNA. Glucose conversion into glycogen was determined in muscle cells exposed to the same conditions and was performed as described (15) .
RNA and DNA extraction from skeletal muscle and muscle cells Skeletal muscle mRNA was extracted from tissue biopsies of 17 women with PCOS and 14 healthy controls. Skeletal muscle DNA was extracted from 15 of the 17 women with PCOS, (two missing samples were due to insufficient amount of tissue) and from the 14 controls. For gene expression array studies, RNA was extracted with the RNeasy Fibrous Tissue Mini Kit (Qiagen, Sollentuna, Sweden). Total RNA in myotubes was extracted by TRIzol, and expression was measured by RT-PCR. The concentration of mRNA was determined with a NanoDrop Spectrophotometer (Thermo Fisher Scientific, Stockholm, Sweden). For methylation array studies, DNA was isolated with the QIAamp DNA Mini Kit (Qiagen). Nucleic acid concentrations and purity were estimated with a NanoDrop Spectrophotometer. DNA integrity was checked by gel electrophoresis, and RNA quality was determined with an automated electrophoresis station (Experion; Bio-Rad Laboratories AB, Solna, Sweden).
mRNA expression arrays
The global mRNA expression profile in skeletal muscle was analyzed by HumanHT-12 v4 Expression BeadChips (Illumina, CA). cRNA synthesis, including biotin labeling, was carried out using the Illumina TotalPrep RNA Amplification Kit (purchased from Thermo Fisher Scientific) according to the manufacturer's recommendations. Biotin-cRNA complex was then fragmented and hybridized to the probes on the Illumina BeadChip array. Probes were hybridized and stained with streptavidin-Cy3 before visualization with the Illumina HiScan fluorescence camera. The Oligo package from Bioconductor was used to compute Robust Multichip Average expression measures (16) .
Quantitative RT-PCR
We performed SYBR Green RT-PCR reactions to detect and quantify mRNA in human myotubes. Specific pairs of PCR primers for the following genes were used: DYRK1A1, SYNPO2, KLF10, SCP2, NAMPT, FOXO3, ING2, TTN, PPP2R2D, THY1, MAP2K6, YWHAE, and COL1A1 (BioRad, Hercules, CA) (Supplemental Table 9 ). All reactions were performed in triplicate; 1 ng of cDNA was used in all reactions combined with Power SYBR ® Green PCR Master Mix (Applied Biosystems, Hercules, CA) and amplified by Applied Biosystems' StepOnePlus Real-Time PCR System according to the manufacturer's instructions. Gene expression results were normalized (HPRT1). (17) . A Zymo Research methylation kit (D5001-D5002; purchased from Nordic Biolabs AB, Stockholm, Sweden) was used to convert genomic DNA to bisulfite-modified DNA. Briefly, high-quality genomic DNA (500 ng) was fragmented and hybridized on the BeadChip, and the intensities of the signal were measured with a HiScanQ scanner (Illumina).
The bioinformatics analyses were performed as previously described in (18) . In brief, Y chromosome probes, singlenucleotide polymorphism probes, probes with an average detection P value .0.01, and cross-reactive probes were removed. After quality control and filtering, methylation data were obtained for 298,307 CpG sites. b-Values were converted to M-values (M = log 2 [b/(1 2 b)]), which were used for all data analyses. The data were quantile normalized and batch corrected with COMBAT (19) . Differential methylation analysis was performed on the batch-corrected probes using the Limma package in R. To improve interpretation, after all the preprocessing steps, the data were transformed back to b-values ranging from 0% (unmethylated) to 100% (completely methylated) and used for visualization purposes.
Pathway analyses
We applied gene set enrichment analysis (GSEA) (20) to the expression array data using Kyoto Encyclopedia of Genes and Genomes pathways. All probes corresponding to transcripts were used and ranked according to the t statistics in a t test. The GSEA considered pathways with 1 to 500 transcripts.
Statistics
Differences in clinical characteristics between women with PCOS and controls were based on Mann-Whitney U tests. DNA methylation and gene expression differences between cases and controls were based on the eBayes-moderated t test, and false discovery rate (FDR; Benjamini-Hochberg method) analysis was used to correct for multiple testing in the genome-wide analyses. The x 2 test was used to calculate whether the differentially methylated sites on the X chromosome were more than the expected number by chance. In women with PCOS and controls, correlations between DNA methylation and gene expression and correlations between gene expression and circulating testosterone levels, insulin, C-peptide, glucose infusion rate (GIR), homeostatic model assessment of insulin resistance (HOMA-IR), homeostatic model assessment of pancreatic b-cell function (HOMA-B), and adipocyte size were analyzed by Spearman correlations. Data are presented as mean 6 SD. Glucose conversion to glycogen differences were analyzed with the t test. Quantitative RT-PCR data were analyzed with the t test, and data are expressed as fold change 6 SEM.
Results
Clinical characteristics
Women with PCOS had more antral follicles, larger ovaries, and higher Ferriman-Gallwey score and circulating testosterone level than controls (Table 1) . Fasting circulating triglyceride and C-peptide levels and calculated C-peptide index were higher and glucose levels were lower in women with PCOS than in controls, indicating metabolic aberration and insulin resistance (Table 1) . In addition, as previously reported, these women have high adipose tissue androgen concentration and larger adipocyte size than controls (21) .
Phenotypic presentation
Eleven of the 17 women with PCOS met all three PCOS criteria; two had hyperandrogenemia and PCO morphology, one had hyperandrogenemia and irregular cycles, and three had irregular cycles and PCO morphology. Because of small sample sizes, it was not possible to subdivide according to phenotype for genomewide analyses.
Genome-wide mRNA expression in skeletal muscle from women with PCOS and controls
Genome-wide mRNA expression in skeletal muscle was analyzed from 17 of the women with PCOS and 14 of the controls. After correction for multiple testing by FDR, 92 probe sets with an FDR , 5% (q , 0.05) corresponding to 85 unique transcripts were found to be differentially expressed in skeletal muscle from women with PCOS vs controls (Supplemental Table 1 ). In total, 66% of the transcripts were upregulated and 34% were downregulated in women with PCOS, and the absolute expression differences of the transcripts ranged from 21% to 186%. Transcripts with the largest expression differences (.40% and q , 0.05) are presented in Table 2 . The five most differentially expressed genes were DYRK1A, SCP2, SYNPO2, KLF10, and NAMPT ( Fig. 1A-1E ), and a large number of the identified genes are thought to play a role in muscle function and metabolism, including COL1A1 and MAP2K6 (Fig. 1F and 1G ) (22) (23) (24) .
Next, we tested whether sets of biologically-related genes were altered in women with PCOS compared with controls. According to the GSEA, there were significant gene expression alterations in 16 pathways in women with PCOS, of which a majority are involved in the immune response or related to immune diseases (Table 3) . Genes contributing to enrichment for significant gene sets are presented in Supplemental Table 2 . Moreover, selected gene sets representing immune system pathways with a downregulation of HLA genes are shown in Fig. 2 .
We investigated whether any of the genes linked to PCOS, obesity, insulin resistance, or T2D in published genome-wide association studies (P , 5 3 10 28 ; http:// www.ebi.ac.uk/gwas) were differently expressed in skeletal muscle from women with PCOS vs controls (P , 0.05). Sixteen of 144 obesity genes (i.e., ATP2A1, CDKAL1, FANCL, FAT1, GRB14, IQCK, KLF9, MARCH6, MGAT1, PTBP2, RSPO3, RTN4, STAB1, SULT1A2, TBCE, and TBX15); 12 of 148 insulin resistance genes (i.e., APOE, ARAP1, CDKAL1, DYRK1A, ENG, GRB14, MLXIPL, NR1H3, PPARG, PPP1R3B, UHRF1BP1, and ZNF644); and 12 of 87 T2D genes (i.e., ACHE, ARAP1, CDKAL1, CMIP, GRB14, ITGB6, MAEA, PPARG, RBM43, RBMS1, WFS1, and ZFAND6) were differentially expressed in skeletal muscle from women with PCOS vs controls, but none of the genes annotated to the 19 PCOS loci. Because some candidate genes are associated with obesity, insulin resistance, and T2D, the differentially expressed candidate genes correspond to 34 unique genes. We searched for overlap between the significantly differentially expressed genes in muscle in this study and those in our previous study, in which we looked at expression differences in adipose tissue between women with PCOS and controls (4). Of 85 differentially expressed genes in skeletal muscle, 16 genes were also differentially expressed in adipose tissue from women with PCOS compared with controls (q , 0.05; Supplemental Table 3 ). Nine genes were differentially expressed in the same direction in both tissues: CFL2, DDX19B, DVL1, KLF10, MAT2B, NBPF20, SYNPO2, WRNIP1, and YWHAE.
Next, we investigated the overlap between the differentially expressed genes identified in this work (P , 0.05) and those shown in a previous study, which studied mRNA expression in the skeletal muscle of 16 patients with PCOS and 13 healthy controls (11). This previous analysis identified 34 probe sets differentially expressed after controlling for multiple testing (FDR , 0.1). Four of these 34 transcripts (i.e., RAPH1, INO80D, PPIE, and AKTIP) showed expression differences in the same direction (upregulated) as observed in the current study. In a previous study, Skov et al. (11) observed a downregulation of OXPHOS genes (PGC1-a, UCP2, NDUFA3, SDHD, COX7C, and ATP5H) in the muscle of PCOS patients. Our data suggest a downregulation by 36% in skeletal muscle from women with PCOS for the UCP2 gene (P = 0.004; q = 0.12), whereas the remaining five genes were not differentially expressed (P . 0.05).
The binding of transcription factors to promoter regions is an important mechanism by which mRNA expression is regulated. We searched for overrepresentation of DNAbinding motifs in promoter regions of the 85 differentially expressed genes using the Pscan software tool (25) and the JASPAR database (26) . We found significant enrichment for sites binding to EGR1-4, KLF14, KLF16, and SP4. Among the genes encoding these transcription factors, SP4 showed a 19% increased expression in the skeletal muscle of women with PCOS (P = 0.02).
Associations between skeletal muscle gene expression and testosterone levels, measures of insulin sensitivity, and adipocyte size
With Spearman correlations, we tested whether circulating testosterone levels, insulin, C-peptide, GIR measured by euglycemic hyperinsulinemic clamp, HOMA-IR, HOMA-B, or adipocyte size in all subjects was associated with skeletal muscle expression of genes with the largest differences in mRNA levels between women with PCOS and controls (the 41 unique genes presented in Table 2 ). Circulating testosterone correlated positively with the expression levels of 22 genes (e.g., FOXO3, ING2, TTN2, PPP2RD2D, GGTL3, and RASA4) and negatively with the expression of THY1. Insulin correlated positively with the expression of three genes: ING2, MAPKAP1, and GGTL3. C-peptide correlated positively with the expression of 17 genes (e.g., ING2, MAPKAP1, and TTN) and negatively with the expression of two genes: COL1A1 and NBPF20. GIR correlated negatively with the expression of PPP2R2D. HOMA-IR correlated positively with the expression of 11 genes (e.g., ING2, GGTL3, and MAPKAP1) and negatively with COL1A1. HOMA-B correlated positively with the expression of 11 genes (e.g., ING2, MAPKAP1, and PPP2R2D). Adipocyte size correlated positively with the expression of 31 genes (e.g., KLF10, PPP2R2D, NAMPT1, and TRIM23) and negatively with COL1A1. All results are presented in Supplemental Table 4 .
mRNA levels in human muscle cells from female donors after testosterone and insulin exposure
To investigate whether the two key features of PCOS, hyperandrogenism and hyperinsulinemia, are causally involved in differential gene expression, we investigated if primary human muscle cells from female donors (n = 4 donors) exposed to testosterone and/or insulin for 3 days had mRNA expression similar to that of women with PCOS. Also, to determine whether the potential effect of testosterone on mRNA is mediated via classic nuclear receptors, the specific AR antagonist bicalutamide was added. For these experiments, we selected a total of 13 genes, including the top five genes with the largest expression differences between women with PCOS and controls (DYRK1A, SYNPO2, KLF10, SCP2, and NAMPT); four genes with significantly higher expression in women with PCOS and positive correlations with testosterone and measures of insulin resistance (FOXO3, ING2, TTN, and PPP2R2D); one gene with significantly lower expression in women with PCOS and negative correlation with testosterone (THY1); two genes with significantly higher expression in women with PCOS and positive correlation with measures of insulin resistance (MAP2K6 and YWHAE); and one gene with significantly lower expression in women with PCOS and negative correlation with measures of insulin resistance (COL1A1).
The mRNA expression of KLF10, which is upregulated in both adipose tissue and skeletal muscle biopsies from women with PCOS and correlates positively with adipocyte size, was upregulated by insulin [after both short (2 hours) and long (3 days) time exposures] with no effect of testosterone alone in human muscle cells from female donors (Fig. 3A) . The effect of insulin was attenuated when the AR antagonist bicalutamide was added. Three days of testosterone exposure resulted in decreased mRNA levels of MAP2K6, COL1A1 (Fig. 3B  and 3C ), FOXO3, and ING2 (Supplemental Table 5 ). The effect of testosterone on MAP2K6 was attenuated when the AR antagonist bicalutamide was added (Fig. 3B) . mRNA expression of PP3RAD was downregulated by testosterone in combination with insulin exposure after both long and short exposure times, and this effect was blocked by bicalutamide exposure (Supplemental Table 5 ). Three days of testosterone exposure in combination with 2 hours of insulin decreased TTN and YWHAE expression, and the effect was no longer significant in combination with bicalutamide (Supplemental Table 5 ). DYRK1A expression was upregulated by bicalutamide exposure but not by testosterone or insulin (Supplemental Table 5 ). The expression of NAMPT, SYNOP2, or THY1 was not affected by any stimulation in human muscle cells.
Effect of androgens on glucose conversion to glycogen in cultured skeletal muscle cells Next, we investigated the effect of insulin, testosterone, and bicalutamide on glucose conversion to glycogen in human muscle cells from female donors (n = 4 donors). The basal and insulin-stimulated levels of glucose-toglycogen conversion were measured in cells exposed to ethanol (control), insulin and testosterone, and bicalutamide (Fig. 4) . Short-term (2-hour) insulin stimulation increased the glucose-to-glycogen conversion rate with no additional effect of testosterone with or without bicalutamide exposure (Fig. 4) . Three days of insulin exposure led to insulin resistance with a glucose conversion rate similar to that of unstimulated cells, with no effect of testosterone. Interestingly, insulin, testosterone, and bicalutamide for 3 days increased glucose conversion to glycogen compared with 3 days of insulin alone (Fig. 4) . There was no additive effect of testosterone in combination with insulin, suggesting a direct effect of insulin.
Genome-wide DNA methylation in skeletal muscle from women with PCOS and controls Finally, we studied the global DNA methylation pattern with the Infinium HumanMethylation450 BeadChip in skeletal muscle from 15 of the women with PCOS and 14 of the controls. After quality control and filtering, methylation data were obtained for 298,307 CpG sites. To evaluate the global human methylome in skeletal muscle tissue, we calculated the average level of methylation for all sites divided into groups on the basis of either their location in relation to the nearest gene (Supplemental Fig. 1A ) or in relation to CpG islands (Supplemental Fig. 1B ). There were no significant differences in average DNA methylation for these regions between women with PCOS and controls. The average methylation level was high within the gene body, 3
0 untranslated region, and intergenic regions, it was low in TSS1500, TSS200, 5 0 untranslated region, and the first exon (Supplemental Fig. 1A ). Moreover, the methylation level was low within CpG islands and intermediate within shores, whereas shelves and open sea showed the highest methylation levels (Supplemental Fig. 1B) . Of the ;300,000 analyzed CpG sites, 17,317 were differentially methylated in skeletal muscle from women with PCOS compared with controls (P , 0.05) (Supplemental Table 6 ). Of these, 11,298 sites had increased methylation and 6019 sites had decreased methylation in women with PCOS. Of the sites with P , 0.05, 359 (;2%) are located on the X chromosome, which is not more than expected by chance. Two CpG sites remained significant after FDR correction (q , 0.05): cg00973947 (annotated to C3orf58) and cg10074626 (intergenic).
We then restricted the analyses to 501 CpG sites in or near the 85 transcripts significantly differentially expressed between women with PCOS and controls. We found that 21 of the significantly differentially expressed genes had one or more CpG sites in which DNA methylation differed between women with PCOS and controls (in total, 24 CpG sites; P , 0.05) (Supplemental Table 7 ). Among these, 58% had methylation and expression differences going in the opposite direction, whereas 42% had differences going in the same direction. The DNA methylation of cg00697125 (KLF10) changed in the same direction (Supplemental Table 7 ) as changes in gene expression (Fig. 1D) , whereas DNA methylation of cg14562086 (COL1A1) and cg07905199 (MAP2K6) changed in the opposite direction (Supplemental Table 7 ) to that of mRNA expression (Fig. 1F and 1G) . Associations between mRNA expression and DNA methylation
We performed Spearman correlations between mRNA expression and DNA methylation for the differentially expressed transcripts. DNA methylation of 41 sites corresponding to 23 genes was significantly associated with gene expression (P , 0.05) (Supplemental Table 8 ). Sixty-eight percent of the correlations were negative, and 32% of the correlations were positive. The most significant positive correlation was seen between SCMH1 and cg15962197 (r = 0.69; P = 0.0005), and the most significant negative correlation was seen between PDE4DIP and cg05771459 (r = 20.66; P = 0.001) (Fig. 5A and 5B).
Furthermore, of DNA methylation and gene expression that changed in opposite directions (Supplemental Table 7), there was a significant negative correlation between MAP2K6 and cg07905199 (r = 20.50; P = 0.019) and a significant negative correlation between COL1A1 and cg14562086 (r = 20.47; P = 0.027) (Supplemental Table 8 ).
Discussion
Skeletal muscle insulin resistance in women with PCOS is reflected by impaired insulin-stimulated glucose disposal (27) , but the mechanisms behind it are largely unknown. In the current study, we investigated both the transcriptome and the methylome in skeletal muscle from women with PCOS and from age-, weight-and BMImatched controls. The study showed that women with PCOS have altered skeletal muscle gene expression that is associated with specific changes in skeletal muscle DNA methylation. It has been hypothesized that the molecular mechanisms underlying insulin resistance in PCOS differ from those seen in obesity and T2D (6) . Our study provides support for epigenetic and transcriptional changes in skeletal muscle, that, in part, may explain metabolic abnormalities seen in these women.
To provide insight into eventual epigenetic dysfunction in skeletal muscle of women with PCOS, we performed comprehensive DNA methylation profiling. We observed only two CpG sites with significant differences in DNA methylation after correction for multiple testing, which may be due to the lack of power or small differences between cases and controls. However, ;30% of the differentially expressed genes in women with PCOS in this study correlated with DNA methylation levels of CpG sites in or near the gene, indeed supporting the role of DNA methylation in affecting gene expression in these individuals. Some of the genes with the largest expression differences and with influence on skeletal muscle metabolism (e.g., MAP2K6 and COL1A1) were associated with DNA methylation. Other epigenetic mechanisms, such as histone modifications and microRNAs, could also be involved in transcriptional regulation and remain to be investigated in future studies.
The most overexpressed gene in the skeletal muscle of women with PCOS was DYRK1A. DYRK1A encodes an inhibitor of glycogen synthase kinase-3 that phosphorylates glycogen synthase directly and thus plays an important role in the regulation of glycogen synthesis in skeletal muscle (28, 29) . To investigate whether hyperandrogenism Another interesting gene among the most differentially expressed was FOXO3, which encodes a transcriptional activator involved in skeletal muscle homeostasis and is important for proteasome degradation (loss of muscle mass). FOXO transcription factors are activated by oxidative stress and have been implicated in glucose metabolism, cell cycle regulation, and mitochondrial metabolism and autophagy (31) . In our study, FOXO3 expression was upregulated in skeletal muscle tissue from women with PCOS and had a strong positive correlation with circulating testosterone, indicating that increased oxidative stress could be due to androgen excess. In contrast, FOXO3 expression was decreased by long-term insulin and testosterone stimulation in human muscle cells. However, the decreased expression was blocked by administration of the AR blocker, indicating that testosterone may have a regulatory role. Previously, it was shown that skeletal muscle gene expression of insulin-signaling molecules is downregulated in subjects with T2D but upregulated in their first-degree relatives (32) . Similarly, FOXO3 was decreased in subjects with T2D and upregulated in relatives with hyperinsulinemia (32) . This is in line with our data demonstrating increased FOXO3 expression in skeletal muscle in insulinresistant women with PCOS and decreased expression of FOXO3 in muscle cells under hyperinsulinemic/ hyperandrogenic conditions.
A previous study showed decreased expression of genes involved in mitochondrial oxidative metabolism in skeletal muscle from women with PCOS (11) . In agreement with the previous study, we found decreased expression of UCP2 in women with PCOS. However, we did not find support for dysregulation of PGC-1a or the oxidative phosphorylation pathway. The subjects included in the previous study were selected as the most insulin resistant from a larger cohort and had a higher BMI than the subjects included in our study, which may explain some of the differences in the results between the two studies (11) .
NAMPT, encoding visfatin, was one of the most upregulated genes in muscle from women with PCOS. Visfatin plays an important role in mitochondrial biogenesis and promotes glucose uptake in muscle cells (33) . We speculate that the upregulation of visfatin may serve as a protective mechanism to compensate for decreasing insulin sensitivity in the women with PCOS included here. Adipocyte size, which is one of the strongest factors explaining insulin resistance in women with PCOS (34), showed a strong positive correlation with NAMPT expression in our study, indicating that there may be cross talk between skeletal muscle and adipose tissue.
Expression of KLF10, which encodes a transcriptional repressor that regulates the circadian expression of genes involved in lipogenesis, gluconeogenesis, and glycolysis (35, 36) , was higher in skeletal muscle of women with PCOS. In addition, increased mRNA levels was associated with increased DNA methylation in the KLF10 promoter. Of note, KLF10 expression correlated positively with adipocyte size and is increased in the adipose tissue in women with PCOS (4), although the role of KLF10 in PCOS is unknown. However, hepatic overexpression of Klf10 is associated with increased blood glucose levels and impaired glucose tolerance, and hepatic knockdown of Klf10 in mice leads to decreased glucose levels and improvement of glucose tolerance (37) . In contrast, male global Klf10 knockout mice display hyperglycemia and increased hepatic glucose production. There may be sex-and tissue-dependent differences because Klf10 knockout females are normoglycemic but have higher plasma triglyceride levels (35) . In this study, KLF10 expression was increased only by insulin stimulation and not by testosterone in stimulated myotubes, which is in line with previous studies (22, 38) . Our results suggest that the major driver of dysfunctional KLF10 regulation is hyperinsulinemia and not testosterone; however, testosterone might have an indirect effect, as the AR antagonists blocked gene activation. KLF10 is also an effective repressor of myoblast proliferation (39) , which may also contribute to altered skeletal muscle function in women with PCOS.
COL1A1 expression was downregulated in skeletal muscle biopsies from women with PCOS and correlated negatively with insulin resistance measures, which is in line with the results of first-degree relatives of patients with T2D (32) . The decreased COL1A1 expression may be explained by the hyperandrogenism in these women, as testosterone exposure decreased COL1A1 expression in myotubes. Interestingly, GnRH, which modulates reproductive function and proliferation in many cell types, directly stimulates COL1A1 and fibronectin production (40, 41) . The decrease in COL1A1 expression in myotubes by in vitro testosterone exposure and the weak negative (P = 0.1) correlation between circulating testosterone and COL1A1 expression in skeletal muscle in women with PCOS indicate that testosterone has the potential to regulate COL1A1 expression either directly or via modulation of GnRH secretion. Further, COL1A1 had a parallel increase in DNA methylation of a CpG site in the promoter region, likely contributing to decreased COL1A1 expression.
In our study, the majority of significantly enriched pathways are involved in immune function or immune diseases, emphasizing a role of immune reaction in the pathogenesis of PCOS. The overall presence of thyroid diseases, asthma, and type 1 diabetes is increased in patients who have PCOS vs controls (42, 43) . In addition, recent studies revealed a higher incidence of autoantibodies presented in systemic autoimmune disease in women with PCOS (44) . Interestingly, several genes encoding HLAs, including HLA-G, are among the downregulated genes in these pathways in our study. This finding is consistent with lower levels of HLA-G in the serum of women with PCOS (45) . A growing body of evidence indicates that HLA-G may be protective in inflammatory and autoimmune diseases, further supporting the idea that immune function seems to be impaired in women with PCOS (46) (47) (48) .
In conclusion, this study provides insight into the underlying mechanisms of skeletal muscle insulin resistance in women with PCOS. We showed that PCOS is associated with aberrant skeletal muscle gene expression with dysregulated pathways. Furthermore, we identified specific changes in skeletal muscle DNA methylation that may affect gene expression. Thus, we demonstrated that women with PCOS have epigenetic and transcriptional changes in skeletal muscle that, in part, can explain the metabolic abnormalities seen in these women.
